KR890007752A - 빈크리스틴-함유 생성물 - Google Patents

빈크리스틴-함유 생성물 Download PDF

Info

Publication number
KR890007752A
KR890007752A KR1019880014770A KR880014770A KR890007752A KR 890007752 A KR890007752 A KR 890007752A KR 1019880014770 A KR1019880014770 A KR 1019880014770A KR 880014770 A KR880014770 A KR 880014770A KR 890007752 A KR890007752 A KR 890007752A
Authority
KR
South Korea
Prior art keywords
met
salt
peptide
vincristine
phe
Prior art date
Application number
KR1019880014770A
Other languages
English (en)
Inventor
요하네스 닉콜슨 빅터
Original Assignee
에프-지.엠.헤르만스, 아.데.도우마
악조 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프-지.엠.헤르만스, 아.데.도우마, 악조 엔.브이. filed Critical 에프-지.엠.헤르만스, 아.데.도우마
Publication of KR890007752A publication Critical patent/KR890007752A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fats And Perfumes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Manufacturing Of Micro-Capsules (AREA)

Abstract

내용 없음

Description

빈크리스틴-함유 생성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. (a) 빈크리스틴 또는 그의 염 및 (b) 하기 일반식(I)의 펩타이드 또는 그의 염 또는 Met(X)가 아미노산 라디칼 Met, Met(O) 또는 Met(O2)인 그의 N-아실유도체로 구성된 것을 특징으로 하는 약학적 생성물.
    H-L-Met(X)-L-Glu-L-His-L-Phe-A-B-Y (I)
    상기식에서 A는 아미노산 라디칼 L-Lys, D-Lys, L-Arg 또는 D-Arg, B는 아미노산라디칼 L-Trp 또는 L-Phe, Y는 Gly-Z 또는 Z Z는 히드록실기, 에스테르화된 히드록실기 또는 선택적으로 치환된 아미노기.
  2. 제 1항에 있어서, 식(I)의 펩타이드가 하기식(II)의 펩타이드 또는 그의 염인 생성물.
    H-L-Met(O2)-L-Glu-L-His-L-Phe-D-Lys-L-Phe-OH (II)
  3. 제 1항 또는 제 2항에 있어서, 정맥내 투여용 생성물.
  4. 제 1항 또는 제 2항에 있어서, 주입용 생성물.
  5. 제 3항에 있어서, 1ml당 0.5-2mg의 빈크리스틴 또는 그의 염과 1ml당 10-4-2×10-3mmol의 식(I)의 펩타이드 또는 그의 염 또는 N-아실유도체를 함유하는 것을 특징으로 하는 정맥내 투여용 생성물.
  6. 제 5항에 있어서, 1ml당 0.5-1.5mg의 빈크리스틴 또는 그의 염과 0.35-0.65mg의 식(II)의 펩타이드(분자량 870)를 함유하는 것을 특징으로 하는 생성물.
  7. (a) 빈크리스틴 또는 그의 염 및 (b) 상기 식 (I)의 펩타이드 또는 그의 염 또는 N-아실유도체 모두 효과적인 양을 암 환자에 투여하는 것으로 구성된 암 환자의 치료방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880014770A 1987-11-11 1988-11-10 빈크리스틴-함유 생성물 KR890007752A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL8702688 1987-11-11
NL8702688 1987-11-11

Publications (1)

Publication Number Publication Date
KR890007752A true KR890007752A (ko) 1989-07-05

Family

ID=19850895

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880014770A KR890007752A (ko) 1987-11-11 1988-11-10 빈크리스틴-함유 생성물

Country Status (13)

Country Link
US (1) US5055449A (ko)
EP (1) EP0316030B1 (ko)
JP (1) JPH01163123A (ko)
KR (1) KR890007752A (ko)
AT (1) ATE70454T1 (ko)
AU (1) AU612720B2 (ko)
DE (1) DE3867039D1 (ko)
DK (1) DK628388A (ko)
ES (1) ES2045092T3 (ko)
GR (1) GR3003930T3 (ko)
IE (1) IE883296L (ko)
NZ (1) NZ226915A (ko)
ZA (1) ZA888335B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8110829B2 (en) 2007-05-31 2012-02-07 Lg Display Co., Ltd. Array substrate of liquid crystal display and method for fabricating the same

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4000154A1 (de) * 1990-01-04 1991-07-11 Symbiotec Gmbh Chemotherapeutisches mittel, insbesondere zur behandlung von krebserkrankungen
US5173521A (en) * 1990-06-19 1992-12-22 Mishima Paper Co., Ltd. Absorbent fibrous structure and producing method thereof
WO1993023072A1 (en) * 1992-05-13 1993-11-25 Akzo N.V. Aqueous hexapeptide compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL175174C (nl) * 1972-03-31 1984-10-01 Akzo Nv Werkwijze ter bereiding van een farmaceutisch preparaat met psychofarmacologische werking, dat een peptide of peptide-derivaat als actief bestanddeel bevat, alsmede een werkwijze ter bereiding van deze peptiden.
OA06421A (fr) * 1980-06-10 1981-09-30 Omnium Chimique Sa Procédé de préparation de dérivés N-(vinblastinoyl-23) d'acides aminés et de peptides.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8110829B2 (en) 2007-05-31 2012-02-07 Lg Display Co., Ltd. Array substrate of liquid crystal display and method for fabricating the same

Also Published As

Publication number Publication date
DE3867039D1 (de) 1992-01-30
AU2490688A (en) 1989-05-11
GR3003930T3 (ko) 1993-03-16
DK628388A (da) 1989-05-12
ZA888335B (en) 1989-07-26
EP0316030B1 (en) 1991-12-18
EP0316030A1 (en) 1989-05-17
AU612720B2 (en) 1991-07-18
US5055449A (en) 1991-10-08
ATE70454T1 (de) 1992-01-15
IE883296L (en) 1989-05-11
NZ226915A (en) 1990-08-28
JPH01163123A (ja) 1989-06-27
ES2045092T3 (es) 1994-01-16
DK628388D0 (da) 1988-11-10

Similar Documents

Publication Publication Date Title
MY116665A (en) Camptothecin derivatives
KR880011199A (ko) 신규 펩타이드 화합물, 그의 제조방법 및 그를 함유하는 약학적 조성물
ES2032382T3 (es) Metodo para preparar un medicamento para la prevencion o tratamiento de la endometriosis.
FR2714378B1 (fr) Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant.
KR900006318A (ko) 피페리디닐 벤즈이미다졸
DE69021176D1 (de) Polypeptid und Verfahren zu dessen Herstellung.
KR890005147A (ko) 펩티딜헤테로사이클
KR910007858A (ko) 초기-촉진 및 향상된 진통제로서의 s(+)-이부프로펜-l-아미노산 및 s(+)-이부프로펜-d-아미노산
KR890007752A (ko) 빈크리스틴-함유 생성물
FR2663328B1 (fr) Derives d'hexahydroazepines, un procede pour leur preparation et compositions pharmaceutiques les contenant.
KR880008801A (ko) 비경구 투여용 용액제
SE7416163L (ko)
FR2700166B1 (fr) Dérivés de pyrrolidine, leur préparation et les médicaments les contenant.
KR890003755A (ko) 7- (2- 메틸- 4- 아미노피롤리디닐)나프티리딘 및 퀴놀린 화합물
KR890003403A (ko) 당뇨병의 합병증을 예방하거나 치료하기 위한 제제
KR950700063A (ko) 외상후 스트레스 치료제로서의 브로파로민(Brofaromine as an agent for treating post-traumatic stress)
KR910006270A (ko) 약리적 활성 화합물 제법 및 용도
KR910011258A (ko) 녹내장의 치료방법
RU2056846C1 (ru) Антиоксидант
KR880002516A (ko) 신경병 치료 및 신경재생을 하여주는 약제 조성물
DE69622868D1 (de) Inhibitoren der blutplättchen-aggregation, die c-terminale aminosäurereste mit aminergen seitenketten enthalten
TH33442A (th) อนุพันธ์ของเตตร้าไฮโดรไอโดรไอโซควิโนลีน

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid